Clinical Trials List
2022-10-28 - 2025-11-30
Phase I
Not yet recruiting1
ICD-10C34.90
Malignant neoplasm of unspecified part of unspecified bronchus or lung
ICD-10C34.91
Malignant neoplasm of unspecified part of right bronchus or lung
ICD-10C34.92
Malignant neoplasm of unspecified part of left bronchus or lung
ICD-10C7A.090
Malignant carcinoid tumor of the bronchus and lung
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9162.9
Malignant neoplasm of bronchus and lung, unspecified
-
Trial Applicant
NOVARTIS (TAIWAN) CO., LTD.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- CHAO-CHI HO CHAO-CHI HO Division of Thoracic Medicine
- 沈盈君 Division of Hematology & Oncology
- 徐偉勛 Division of Hematology & Oncology
- James Chih-Hsin Yang Division of Hematology & Oncology
- 蔡子修 Division of Thoracic Medicine
- 許嘉林 Division of Thoracic Medicine
- Chong-Jen Yu Division of Thoracic Medicine
- YEN-TING LIN Division of Cardiovascular Diseases
- JHE-CYUAN GUO Division of Hematology & Oncology
- 楊景堯 Division of Thoracic Medicine
- Yu-Chieh Tsai Division of Hematology & Oncology
- 吳尚俊 Division of Thoracic Medicine
- 施金元 Division of Thoracic Medicine
- TA-CHEN HUANG Division of Hematology & Oncology
- 廖唯昱 Division of Thoracic Medicine
- FU-JEN HSUEH Division of Hematology & Oncology
- 李日翔 Division of Hematology & Oncology
- Chih-Hung Hsu Division of Hematology & Oncology
- HUAI-CHENG HUANG Division of Hematology & Oncology
- 廖斌志 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
12-24 participants
-
Global
125 participants
